wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
Q53394177-3E60A6F6-F37A-49A9-9F6B-5E83BE104DCF
Q53394177-3E60A6F6-F37A-49A9-9F6B-5E83BE104DCF
BestRank
Statement
http://www.wikidata.org/entity/statement/Q53394177-3E60A6F6-F37A-49A9-9F6B-5E83BE104DCF
Development of epidermal growth factor receptor tyrosine kinase inhibitors against EGFR T790M. Mutation in non small-cell lung carcinoma.
P2860
Q53394177-3E60A6F6-F37A-49A9-9F6B-5E83BE104DCF
BestRank
Statement
http://www.wikidata.org/entity/statement/Q53394177-3E60A6F6-F37A-49A9-9F6B-5E83BE104DCF
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
257804e607e383cef6a672cf652e522e999e293c
P2860
A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib.